TrialHaematologica2022

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.

Stéphanie Dulucq et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.